6月30日，基因编译公司Intellia Therapeutics(NTLA.O)盘中涨超30%，近日，公司和再生元制药联合宣布，在研CRISPR体内基因组编辑疗法NTLA-2001在1期临床试验中获得积极结果。单剂NTLA-2001导致血清中的转甲状腺素蛋白水平(TTR)平均下降87%，在第28天TTR降低幅度最大可达96%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments